About us
ImClone Systems is a fully integrated global biopharmaceutical company committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. On November 24, 2008, ImClone Systems became a wholly-owned subsidiary of Eli Lilly and Company (NYSE: LLY).
- Website
-
http://www.imclone.com
External link for ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Type
- Public Company
- Founded
- 9184
- Specialties
- Monoclonal antibodies and biopharmaceutical company
Locations
-
Primary
Get directions
-
Get directions